Skip to main content
SURG
NASDAQ Technology

SurgePays Files Preliminary Prospectus for Common Stock and Warrant Offering, Citing Substantial Dilution

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
8
Price
$1.55
Mkt Cap
$39.348M
52W Low
$1.049
52W High
$3.47
Market data snapshot near publication time

summarizeSummary

SurgePays filed a preliminary prospectus for an equity offering of common stock and pre-funded warrants, warning of substantial dilution, to fund its Lifeline business and for working capital. This follows a recent high-interest convertible note issuance and a significant reduction in its ATM program capacity.


check_boxKey Events

  • Preliminary Public Offering Filed

    SurgePays filed a preliminary prospectus supplement for a public offering of common stock and pre-funded warrants. Specific terms, including the number of shares and offering price, are not yet disclosed.

  • Substantial Dilution Expected

    The filing explicitly states that purchasers of common stock and pre-funded warrants in this offering will experience "immediate and substantial dilution" in net tangible book value.

  • Use of Proceeds

    Net proceeds are intended for the expansion of the company's Lifeline business, working capital, and general corporate purposes.

  • ATM Program Capacity Reduced

    The company's At-The-Market (ATM) offering capacity has been significantly reduced to effectively $1, indicating a shift away from this method for future capital raises.


auto_awesomeAnalysis

SurgePays has filed a preliminary prospectus supplement for a public offering of common stock and pre-funded warrants. While specific offering terms like the number of shares and pricing are not yet disclosed, the filing explicitly warns of "immediate and substantial dilution" for existing shareholders. This indicates a significant capital raise relative to the company's size and current financial position, which includes negative total shareholders' equity as of September 30, 2025. The proceeds are intended for the expansion of the Lifeline business, working capital, and general corporate purposes, suggesting a critical need for capital to fund operations and growth. Additionally, the company recently issued $500,000 in secured convertible notes at a high interest rate of 14.5%, further highlighting its ongoing capital requirements and the cost of financing. The update to their At-The-Market (ATM) program, reducing available capacity to effectively $1, means this offering is a primary method for raising capital, as the ATM is no longer a viable option for significant funds.

At the time of this filing, SURG was trading at $1.55 on NASDAQ in the Technology sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $1.05 to $3.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SURG - Latest Insights

SURG
Apr 27, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
SURG
Apr 15, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
9
SURG
Apr 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
SURG
Mar 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
SURG
Jan 22, 2026, 12:10 PM EST
Filing Type: 424B5
Importance Score:
9
SURG
Jan 22, 2026, 11:59 AM EST
Filing Type: 8-K
Importance Score:
8
SURG
Jan 21, 2026, 9:39 PM EST
Filing Type: 424B5
Importance Score:
8
SURG
Jan 20, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
SURG
Jan 14, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
SURG
Jan 07, 2026, 4:55 PM EST
Filing Type: 8-K
Importance Score:
7